Apyx Medical Corporation SEC Filings

Apyx Medical Corporation reported that its stockholders approved an amendment to its Certificate of Incorporation at the August 7, 2025 annual meeting to remove Article EIGHTH and replace it with the phrase “intentionally omitted.” On December 8, 2025, the company filed a Certificate of Amendment with the Delaware Secretary of State to put this change into effect, and the full text of the amendment is included as an exhibit.

Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to complete a public offering of its common stock. The Company issued 2,762,431 shares at an offering price of $3.62 per share and granted the underwriter an option to purchase up to an additional 414,365 shares. The offering closed on November 19, 2025, generating approximately $9.4 million in aggregate gross proceeds after a 6.0% underwriting discount and before expenses.

The Company plans to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions of complementary businesses, products or technologies, and repayment of indebtedness it may incur. The transaction was conducted under an existing Form S-3 shelf registration, and customary legal opinions and underwriting documents were filed as exhibits.

Apyx Medical Corporation is conducting a primary offering of 2,762,431 shares of common stock at $3.62 per share, for gross proceeds of about $10,000,000, with an underwriter option for up to 414,365 additional shares. After underwriting fees and estimated expenses, the company expects net proceeds of approximately $9,000,000, which it plans to use for working capital, expanding sales and marketing, capital spending, potential acquisitions and debt repayment.

This financing will increase shares outstanding from 38,251,823 to 41,014,254 (or 41,428,619 if the option is fully exercised) and results in immediate dilution of $3.25 per share to new investors. The filing also highlights recent milestones for the AYON Body Contouring System™, including FDA 510(k) clearance, a soft launch followed by commercial rollout in 2025, and management’s belief that GLP‑1 weight‑loss drug use may ultimately support demand for the company’s Renuvion aesthetic products.

Apyx Medical Corporation plans a primary offering of common stock and pre-funded warrants under its existing Form S-3 shelf registration. Investors may buy either shares or, in lieu of shares, pre-funded warrants that are exercisable for one share of common stock at an exercise price of $0.001 and do not expire, subject to ownership limits.

The company has granted the underwriter a 45-day option to purchase additional common shares. Apyx expects to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions and debt repayment. Shares outstanding were 37,819,478 as of September 30, 2025.

Apyx is a surgical aesthetics company focused on its Helium Plasma Technology, marketed as Renuvion and the AYON Body Contouring System. It recently received FDA 510(k) clearance for AYON and has begun commercial launch, targeting procedures to address loose or lax skin and other aesthetic treatments.

Apyx Medical (APYX) reported Q3 2025 results showing higher sales and narrower losses as it launched the AYON Body Contouring System. Revenue was $12.877 million, up 12.1% from $11.487 million a year ago, driven by a 19.1% increase in Surgical Aesthetics to $11.065 million, while OEM declined 17.6% to $1.812 million. Gross margin improved to 64.4% from 60.5%.

Operating loss narrowed to $0.832 million from $3.635 million, and net loss attributable to stockholders improved to $1.984 million (loss per share $0.05) from $4.703 million ($0.14). For the nine months, revenue was $33.680 million versus $33.880 million, with operating cash outflow of $5.471 million improving from $15.110 million.

Liquidity and leverage: Cash and equivalents were $25.135 million versus $31.741 million at year-end. Long‑term debt, net, was $34.607 million on a $37.5 million term loan bearing interest at one‑month SOFR (floor 5.0%) plus 7.0% (12.0% at September 30, 2025). The company was in compliance with covenants. AYON received 510(k) clearance in May and began commercial launch in September; a 510(k) for label expansion was submitted in October. Shares outstanding were 38,241,905 as of November 5, 2025.

Apyx Medical Corporation furnished an 8-K announcing it issued a press release reporting results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.

The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, or incorporated by reference into Securities Act or Exchange Act filings, except as expressly set forth by specific reference.

Apyx Medical Corporation reported the outcomes of proposals submitted at its annual meeting. Stockholders elected five directors to serve on the board until the 2026 annual meeting, with each nominee receiving between 18.88 million and 19.11 million votes in favor and 6.77 million broker non-votes recorded in those tallies. Shareholders ratified RSM US LLP as the company’s independent registered public accounting firm by a vote of 25,930,634 in favor. A non-binding advisory vote on executive compensation passed with 18,963,101 votes for. A separate advisory vote on frequency favored a one-year option (9,205,086 votes). Stockholders also approved an amendment to delete the text of Article EIGHTH, with 19,047,016 votes for.

Apyx Medical (NASDAQ:APYX) filed a DEF 14A announcing its 2025 Annual Meeting of Stockholders to be held on August 7, 2025. Shareholders will vote on: five key proposals including the election of five directors, ratification of RSM US LLP as auditors, advisory vote on executive compensation, frequency of future say-on-pay votes, and an amendment to delete Article EIGHTH from the Certificate of Incorporation.

The meeting will take place at 9:00 AM EST at Ruskin Moscou Faltischek's offices in Uniondale, NY. The record date for voting eligibility is June 17, 2025. Proxy materials will be distributed to shareholders starting June 27, 2025.